TrialThe New England journal of medicine2019

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Kevan C Herold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.